Altamira Therapeutics Ltd. Research and Development Expense
Altamira Therapeutics Ltd. (CYTOF) reported Research and Development Expense of CHF 2.86 million for the 12-month period ending 2020-12-31, per its 20-F filed 2021-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-03-31
| Period end | Research and Development Expense 12 month |
|---|---|
| 2020-12-31 | 2.86M CHF 20-F · filed 2021-03-31 |
| 2019-12-31 | 3.33M CHF 20-F · filed 2021-03-31 |
| 2018-12-31 | 6.69M CHF 20-F · filed 2021-03-31 |
| 2017-12-31 | 19.21M CHF 20-F · filed 2020-04-16 |